<DOC>
	<DOCNO>NCT01164189</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether temozolomide effective give without bevacizumab treat patient recurrent glioma . PURPOSE : This randomized clinical trial study well temozolomide work without bevacizumab treat patient recurrent glioma .</brief_summary>
	<brief_title>Bevacizumab Recurrent Grade II III Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To document activity combination temozolomide plus bevacizumab temozolomide alone patient recurrent grade II grade III glioma without 1p/19q co-deletion . Secondary - To characterize safety treatment patient . - To document quality life cognitive functioning , measure clinical benefit , patient . - To explore qualification occurrence prognostic and/or predictive biomarkers activity efficacy patient . ( exploratory ) - To document discordance RANO Macdonald 's criterion evaluation response progression . ( exploratory ) OUTLINE : This multicenter study . Patients stratify accord institution , initial histology ( grade II v grade III ) , WHO performance status ( 0-1 v 2 ) , prior treatment ( radiotherapy [ RT ] alone , temozolomide [ TMZ ] procarbazine , lomustine vincristine [ PCV ] alone vs TMZ/RT ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral temozolomide daily day 1-5 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . - Arm II : Patients receive oral temozolomide arm I bevacizumab IV 90 minute day 1 15 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients complete neurocognitive questionnaire ( i.e. , Hopkins Verbal Learning test , Controlled Oral Word Association test , Trail Making test A B ) . Quality-of-life assessment questionnaire , include EORTC QLQ-C30 EORTC-BN20 , complete patient caregivers/relatives baseline periodically . Frozen tumor biopsy paraffin block blood specimen collect bio-banking translational research . After completion study therapy , patient follow every 3 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically proven grade II grade III astrocytoma , oligodendroglioma oligoastrocytoma accord WHO 2007 initial diagnosis . Demonstrated absence 1p/19q codeletion accord local diagnosis . Availability biological material central review process translational research project First recurrence initial treatment either radiotherapy and/or chemotherapy . Enhancing recurrence MRI scan . For non operated patient , recurrent disease must least one bidimensionally measurable contrastenhancing lesion clearly define margin MRI scan , minimal diameter 10 mm , visible 2 axial slice 5 mm apart , base MRI scan do within two week prior start randomisation . Stable decrease dosage steroid 7 day prior baseline MRI scan . No one line chemotherapy ( concurrent adjuvant temozolomide chemotherapy consider one line chemotherapy ) If give , chemotherapy must consist either temozolomide PCV , patient must chemotherapy treatment 6 month without progression . No radiotherapy within three month prior diagnosis progression No radiotherapy dose 65 Gy , stereotactic radiosurgery brachytherapy unless recurrence histologically proven No current recent ( within 4 week randomization ) treatment another investigational drug No prior treatment Bevacizumab VEGF inhibitor VEGFReceptor signal inhibitor No invasive procedure ( surgical resection , open biopsy , significant traumatic injury major surgery involve entry body cavity ) within 4 week prior randomization , anticipation need major surgery course study treatment . No core biopsy ( exclude intracranial biopsy ) minor surgical procedure within 7 day prior randomization . Placement central vascular access device ( CVAD ) perform least 2 day prior bevacizumab administration allow . Patient may undergo surgery recurrence . If operate , residual measurable disease surgery require histology must confirm recurrence . Craniotomy intracranial biopsy site must adequately heal free drainage cellulitis , underlie cranioplasty must appear intact time randomisation . No previous malignancy , except previous malignancy treat curative intent 5 year prior randomisation , except adequately control limited basal cell carcinoma skin , squamous carcinoma skin carcinoma situ cervix Absence cardiovascular disorder , include limit : No history myocardial infarction , unstable angina within 6 month prior randomisation No `` New York Heart Association '' ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication . No significant vascular disease ( e.g . aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior randomisation No prior history hypertensive crisis hypertensive encephalopathy No inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 Hg ) Absence thrombotic hemorrhagic event , include limit : No evidence recent hemorrhage MRI brain . However , patient clinically asymptomatic presence hemosiderin , resolve hemorrhagic change relate surgery , presence punctate hemorrhage tumor permit entry study No history evidence inherit bleed diathesis coagulopathy risk bleeding . No arterial venous thrombosis ≤ 12 month prior randomization No history stroke TIAs within 6 month prior randomization No history pulmonary haemorrhage/haemoptysis ≥ grade 2 accord NCICTCAE version 4.0 criterion within 1 month prior randomization Absence current recent ( within 10 day first dose Bevacizumab ) use aspirin ( &gt; 325 mg/day ) NSAID antiplatelet activity treatment dipyramidole , ticlopidine , clopidogrel cilostaz . International normalized ratio ( INR ) &gt; 1.5 ULN activate partial thromboplastin time ( aPTT ) &gt; 1.5 × ULN . Patients use fulldose anticoagulant baseline exclude study ; prevention thrombosis lowdose anticoagulant allow Absence know hypersensitivity part Bevacizumab Temozolomide formulation . Chinese hamster ovary cell product recombinant human humanize antibody . No underlie previous condition could interfere treatment , include limit : No history intracranial abscess within 6 month prior randomisation No clinically serious ( judged investigator ) nonhealing wound , active skin ulcer incompletely heal bone fracture . No history active gastroduodenal ulcer ( ) . No history abdominal fistula well nonGI fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior inclusion . No evidence active infection require hospitalization antibiotic , within 2 week prior randomisation . No disease , interfere follow . Normal hematological function : neutrophil ≥ 1.5 x 109 cells/l , platelet ≥100 x 109 cells/l Hb ≥ 6.2 mmol/l ( 9.9 g/dl ) . Normal liver function : bilirubin &lt; 1.5 x upper limit normal range ( ULN ) , alkaline phosphatase transaminase ( ASAT ) &lt; 2.5 x ULN , INR &lt; 1.5 ULN . Normal renal function : calculate ( CockcroftGault ) measure creatinine clearance &gt; 30 mL/min ; Urine dipstick proteinuria &lt; 2+ . Patients ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤1 g protein/24 hr . Age ≥ 18 year WHO Performance status 0 2 Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study manner risk pregnancy minimize . In general , decision appropriate method prevent pregnancy determine discussion investigator study subject . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Post menopause define : amenorrhea ≥ 12 consecutive month without another cause woman irregular menstrual period hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( eg , vasectomy ) consider childbearing potential . Women child bear potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior start investigational product . Female patient within one year entering menopause well male must agree use effective nonhormonal method contraception treatment period least 6 month last study treatment . Female breast feed Absence psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule ; condition assess patient randomization trial . Before patient randomization study relate procedure ( would perform part standard care ) , write informed consent must give accord ICH/GCP , national/local regulation . Informed consent also give biological material store used future research brain tumor . All indicated timeline absolute value request eligibility criterion must adhere . However , maximum +/ 10 % reference value laboratory parameter maximum +/ 2 day timeline may acceptable . Discussion Headquarters study coordinator encourage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>